Concurrent disorders (Canadian terminology; equivalent to dual diagnosis in U.S. literature) describes the situation where a patient has both a mental health disorder and a substance use disorder — though the term is also used more broadly for any clinically significant comorbidity between mental health conditions. Common patterns: TRD (treatment-resistant depression) with comorbid AUD (alcohol use disorder) or other SUD (substance use disorder); PTSD (post-traumatic stress disorder) with comorbid SUD; depression with comorbid anxiety; eating disorder with comorbid TRD or PTSD; bipolar with comorbid SUD. Concurrent disorders are the rule, not the exception, in clinical practice — roughly 50-80% of patients in addiction treatment have comorbid mental illness and roughly 50% of patients with severe mental illness have comorbid SUD (CCSA; CRISM). Integrated care — concurrent treatment of both conditions by a coordinated team — is the standard-of-care framework. This article is a Canadian evidence-and-pathway guide to psychedelic-assisted therapy in concurrent disorders contexts: treatment sequencing considerations, integrated care models, and substance-specific evidence across TRD+SUD, PTSD+SUD, ED+TRD, anxiety+depression, and other patterns.
Key takeaways
- Concurrent disorders are the rule, not the exception: ~50-80% of addiction treatment patients have comorbid mental illness; ~50% of severe mental illness patients have comorbid SUD.
- Integrated care — concurrent treatment of both conditions by a coordinated team — is the standard-of-care framework (CRISM, ASAM, NICE).
- TRD + SUD: Bogenschutz 2022 JAMA Psychiatry psilocybin AUD has secondary depression signal; Dakwar 2020 ketamine AUD with motivational enhancement therapy; Spravato approved for TRD covers TRD primary in TRD+SUD context.
- PTSD + SUD: high-prevalence comorbidity (>50% in trauma-exposed populations); MDMA-AT for PTSD has comorbid SUD analyses suggesting signal.
- Anxiety + Depression: most common comorbidity pattern; psychedelic-assisted therapy evidence concentrated in depression with anxiety as secondary outcome (Goodwin 2022, Carhart-Harris 2021).
- ED + TRD/PTSD: emerging psilocybin AN evidence; trauma-ED comorbidity makes MDMA-AT relevant for ED+PTSD.
- Bipolar + SUD: complex; mood stabilizer coordination essential; psilocybin/MDMA generally contraindicated.
- Treatment sequencing: integrated concurrent treatment generally preferred over sequential. Psychedelic-assisted therapy as adjunct to integrated care.
Defining concurrent disorders
The term "concurrent disorders" is Canadian (CCSA, CMHA usage); "dual diagnosis" is the U.S. equivalent. The term is used in two senses:
- Narrow: comorbidity between mental health disorder and substance use disorder
- Broad: any clinically significant comorbidity between mental health conditions
Major concurrent disorder patterns:
- TRD + AUD or other SUD
- PTSD + SUD
- MDD + Anxiety disorder (highest-prevalence pattern)
- ED + TRD or PTSD
- Bipolar + SUD
- Personality disorder + SUD or mood
- Concurrent multiple SUDs (polysubstance)
- MH + chronic pain (anxiety/depression and chronic pain comorbid)
Why integrated care?
CRISM and ASAM guidance: integrated concurrent treatment is preferred over sequential because:
- Sequential treatment fails to address the bidirectional reinforcement
- Patients often relapse on one condition when treated for only the other
- Comprehensive engagement with both conditions improves outcomes
Integrated care models in Canada:
- CMHA RAAM clinics: rapid access addiction medicine integrated with mental health
- Provincial mental health and addictions units: integrated by design
- Specialty programs: trauma + SUD specialty programs, ED + co-occurring units, bipolar + SUD specialty clinics
The concurrent-disorder evidence map for psychedelic-assisted therapy
TRD + SUD
- Bogenschutz et al. 2022 JAMA Psychiatry AUD: psilocybin-assisted therapy showed reduction in heavy drinking days; secondary depression measures also improved
- Dakwar et al. 2020 AUD: ketamine + motivational enhancement therapy
- Spravato for TRD primary: covered through standard pathways; SUD context does not contraindicate but requires care coordination
PTSD + SUD
- High-prevalence comorbidity: ≥50% of PTSD patients have SUD; ≥50% of SUD treatment patients have PTSD or trauma history
- MDMA-AT MAPP1/MAPP2: patients with comorbid SUD were not entirely excluded; subgroup analyses ongoing
- Trauma-informed addiction care: foundational
- Sequencing: typically address active SUD first, then trauma — but increasingly integrated approaches
- Concurrent SUD activity considerations: most psychedelic-assisted therapy programs require some period of SUD remission for active enrollment
MDD + Anxiety disorder
- Most common comorbidity pattern; psilocybin and ketamine evidence concentrated in TRD with anxiety as secondary outcome
- Goodwin 2022 COMP001: secondary anxiety measures improved
- Carhart-Harris 2021 NEJM: secondary anxiety measures
ED + TRD or PTSD
- Trauma-ED comorbidity is well-documented; MDMA-AT for PTSD with comorbid ED is emerging
- Psilocybin AN evidence (Peck 2023) is in primary AN; comorbidity considerations apply
Bipolar + SUD
- Complex; mood stabilizer coordination essential
- Psilocybin and MDMA generally contraindicated in bipolar populations regardless of SUD comorbidity
- Off-label ketamine with mood stabilizer: Diazgranados 2010 / Zarate 2012 framework applies; SUD adds complexity
Concurrent multiple SUDs
- Polysubstance use complicates psychedelic-assisted therapy candidacy
- Comprehensive addiction medicine assessment essential
Decision framework — concurrent disorders sequencing
| Step | Question | Consequence |
|---|---|---|
| 1 | What's the primary clinical concern (most acutely impairing)? | Address the most-impairing condition first while integrating the other |
| 2 | Is patient stable enough for psychedelic-assisted therapy candidacy? | Active SUD intoxication, severe ED instability, acute suicidality, active mania = not appropriate |
| 3 | Is integrated care team in place? | Concurrent disorder treatment without integrated team is suboptimal |
| 4 | What substances/comorbidities? | Bipolar = mood stabilizer coordination; ED = medical stability; SUD = remission considerations |
| 5 | What's the risk-benefit assessment? | Comprehensive assessment by qualified prescribing physician |
Canadian access pathways
Integrated concurrent disorder care
- CMHA RAAM clinics: provincial rapid access addiction medicine integrated with MH
- Provincial concurrent disorder programs: most provinces have specialty programs
- CRISM Canadian opioid use disorder clinical practice guideline: foundational for OUD comorbidity
- CCSA resources: education, family support, care navigation
Psychedelic-assisted therapy in concurrent disorder context
- Spravato for TRD primary in TRD+SUD: covered through standard pathways
- Off-label ketamine in concurrent disorder context: increasing real-world use; integrated care coordination essential
- MDMA-AT for PTSD primary in PTSD+SUD: SAP-pathway case-by-case
- Psilocybin SAP for primary indications with comorbidity: case-by-case
For more detail see Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy, Addiction and Psychedelic-Assisted Therapy, Bipolar Disorder and Psychedelic-Assisted Therapy Considerations, and Eating Disorders and Psychedelic-Assisted Therapy.
What the evidence does NOT say
- Concurrent disorder evidence is generally underdeveloped in psychedelic-assisted therapy RCTs — many trials exclude active SUD or unstable concurrent conditions.
- Treatment sequencing: optimal sequencing in concurrent disorders is clinically individualized, not algorithm-determined.
- Active SUD: most psychedelic-assisted therapy programs require some period of SUD remission for active enrollment; patients in early recovery typically need addiction medicine stabilization first.
- Active eating disorder instability: medical instability is contraindication.
- Active mania or mixed episode: contraindication for any psychedelic-assisted therapy.
- Acute suicidality: requires comprehensive psychiatric care first.
- Polysubstance use: complicates candidacy; comprehensive addiction medicine assessment essential.
- Personality disorder + SUD or mood: less-studied population in psychedelic-assisted therapy RCTs; comprehensive assessment essential.
How ATMA CENA works with concurrent disorder patients
ATMA CENA's concurrent disorder pathway:
- Comprehensive intake: detailed psychiatric history, SUD history, comorbidity mapping, current treatment team, medication regimen
- Integrated care coordination is essential: ATMA CENA will work with patient's existing addiction medicine, ED specialist, psychiatrist, or trauma therapist — not displace those relationships
- Three-phase model: preparation + dosing + integration — adapted for concurrent disorder context
- Coordinated care: existing integrated care team remains primary
- Honest framing: ATMA CENA will route patients with active concurrent disorder instability to standard integrated care first
Frequently asked questions
What's the difference between concurrent disorders and dual diagnosis? "Concurrent disorders" is Canadian terminology (CCSA, CMHA); "dual diagnosis" is U.S. equivalent. Both refer to comorbidity between mental health disorders and substance use disorders, sometimes broader.
How common are concurrent disorders? Roughly 50-80% of addiction treatment patients have comorbid mental illness. Roughly 50% of severe mental illness patients have comorbid SUD. Concurrent disorders are the rule, not the exception.
What's integrated care? Concurrent treatment of both mental health and substance use disorders by a coordinated team. CRISM and ASAM guidance: integrated concurrent treatment is preferred over sequential.
Can I do psychedelic-assisted therapy if I'm in early recovery from SUD? Most programs require some period of SUD remission for active enrollment. Patients in early recovery typically need addiction medicine stabilization first. Integrated care coordination essential.
What about TRD with comorbid AUD? Bogenschutz 2022 psilocybin-AUD evidence; Dakwar 2020 ketamine-AUD evidence. Spravato covers TRD primary; SUD context does not contraindicate but requires care coordination.
What about PTSD with comorbid SUD? High-prevalence comorbidity (≥50% in trauma-exposed populations). MDMA-AT MAPP1/MAPP2 PTSD trials have subgroup analyses ongoing. Trauma-informed addiction care is foundational.
What about bipolar with comorbid SUD? Complex. Mood stabilizer coordination essential. Psilocybin and MDMA generally contraindicated. Off-label ketamine with mood stabilizer per Diazgranados/Zarate framework, plus SUD-specific care.
What about ED with comorbid TRD or PTSD? Trauma-ED comorbidity is well-documented. MDMA-AT for PTSD with comorbid ED is emerging. Psilocybin AN evidence (Peck 2023) in primary AN — ED specialist coordination essential.
What if I have multiple concurrent disorders? Comprehensive integrated care assessment essential. Polysubstance use, complex psychiatric comorbidity, and unstable concurrent conditions complicate candidacy. Standard integrated care first; psychedelic-assisted therapy adjunct if appropriate.
What's the role of family / support? Concurrent disorder treatment benefits from family/support involvement where appropriate. ATMA CENA's three-phase model includes family integration consideration.
Sources
- Bogenschutz MP, Ross S, Bhatt S, et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. JAMA Psychiatry, 79(10):953-962. PMID: 36014054.
- Dakwar E, Levin F, Hart CL, et al. (2020). A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder. Am J Psychiatry, 177(2):125-133. PMID: 32340401.
- Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
- Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
- Diazgranados N, Ibrahim L, Brutsche NE, et al. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 67(8):793-802. PMID: 20530009.
- Peck SK, Shao S, Gruen T, et al. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine, 29(8):1947-1953. PMID: 37464048.
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Canadian Centre on Substance Use and Addiction (CCSA) — Concurrent Disorders: https://ccsa.ca/concurrent-disorders
- Canadian Mental Health Association (CMHA): https://cmha.ca/
- CRISM Canadian opioid use disorder national clinical practice guideline: https://crism.ca/projects/opioid-use-disorder-national-guideline/
- ASAM (American Society of Addiction Medicine) — clinical guidelines: https://www.asam.org/quality-care/clinical-guidelines
- NICE clinical guideline CG120 — Coexisting severe mental illness (psychosis) and substance misuse: https://www.nice.org.uk/guidance/cg120
Related articles
- Treatment-Resistant Depression and Psychedelic-Assisted Therapy
- PTSD and Psychedelic-Assisted Therapy
- Addiction and Psychedelic-Assisted Therapy
- Anxiety Disorders and Psychedelic-Assisted Therapy
- Eating Disorders and Psychedelic-Assisted Therapy
- Bipolar Disorder and Psychedelic-Assisted Therapy Considerations
- Burnout, Moral Injury, and Psychedelic-Assisted Therapy
- Insurance Coverage for Psychedelic-Assisted Therapy in Canada
Last updated: 2026-05-06